| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.076 | 0.05 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.068 | 0.05 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.05 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.05 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.05 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.05 |
| mRNA | Vinorelbine | GDSC1000 | pan-cancer | AAC | -0.07 | 0.06 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.06 |